Radically more accurate cancer prognostics using AI
DoMore Diagnostics AS was established in 2020 originating from the research project DoMore!, which was initialized as Oslo University Hospital in 2016. With support from the Research Council of Norway, DoMore has developed a world-leading technology for accurate diagnostics of colorectal cancer. The solution predicts the course of the disease so that the patient can receive the best adapted treatment.
DoMore Diagnostics has been granted an exclusive license to commercialize the method in the prognosis of colorectal cancer, lung cancer and prostate cancer. In 2021, the company raised NOK 15 million from growth fund Norselab and technology entrepreneur Øyvind Grotmol for growth and international scaling of the company.